首页> Advances in therapy> Outcomes of Patients with COPD Treated with ICS/LABA Before and After Initiation of Single-Inhaler Triple Therapy with Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI).

Outcomes of Patients with COPD Treated with ICS/LABA Before and After Initiation of Single-Inhaler Triple Therapy with Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI).

导出 OA

翻译打印收藏纠错

第一作者： Meredith,McCormack

第一单位： Pulmonary and Critical Care Medicine, Johns Hopkins University, Baltimore, MD, USA.

作者： Meredith,McCormack ^[1] ; Rosirene,Paczkowski ^[2] ; Noelle N,Gronroos ^[3] ; Stephen G,Noorduyn ^[4] ; Lydia,Lee ^[5] ; Phani,Veeranki ^[3] ; Mary G,Johnson ^[3] ; Emmeline,Igboekwe ^[6] ; Kristin,Kahle-Wrobleski ^[7] ; Reynold,Panettieri ^[8]

作者单位： Pulmonary and Critical Care Medicine, Johns Hopkins University, Baltimore, MD, USA. ^[1] Value Evidence and Outcomes, R&D Global Medical, GSK, Collegeville, PA, 19426-0989, USA. rosirene.x.paczkowski@gsk.com. ^[2] Health Economics and Outcomes Research, Optum, Eden Prairie, MN, USA. ^[3] Global Value Evidence and Outcomes, GSK, Mississauga, ON, Canada.;Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, ON, Canada. ^[4] Value Evidence and Outcomes, R&D Global Medical, GSK, Collegeville, PA, 19426-0989, USA.;Center for Health Outcomes, Policy and Economics, Rutgers School of Public Health, Piscataway, NJ, USA. ^[5] US Medical Affairs, R&D Global Medical, GSK, Durham, NC, USA. ^[6] Value Evidence and Outcomes, R&D Global Medical, GSK, Collegeville, PA, 19426-0989, USA. ^[7] Rutgers Institute for Translational Medicine and Science, New Brunswick, NJ, USA. ^[8]

关键词 COPD Dual therapy Exacerbations FF/UMEC/VI HCRU ICS/LABA Single-inhaler triple therapy